The role of lymphadenectomy in minimally invasive urologic oncology

Journal of Endourology

Volumn 24, Issue 8, 2010, Pages 1229-1240

  Weizer, Alon Z ^a   Montgomery, Jeffrey S ^a  

^a UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; BLEOMYCIN; CISPLATIN; ETOPOSIDE; PLATINUM DERIVATIVE; PROSTATE SPECIFIC ANTIGEN;

BLADDER CANCER; CANCER CHEMOTHERAPY; CANCER STAGING; CLINICAL TRIAL; COMPUTER ASSISTED TOMOGRAPHY; CYSTECTOMY; DISEASE FREE SURVIVAL; HEMATOMA; HUMAN; INFECTION; INGUINAL LYMPHADENECTOMY; KIDNEY CARCINOMA; LAPAROSCOPIC SURGERY; LYMPH NODE DISSECTION; LYMPHADENECTOMY; LYMPHOCELE; MINIMALLY INVASIVE PROCEDURE; MINIMALLY INVASIVE SURGERY; MULTIPLE CYCLE TREATMENT; NEPHRECTOMY; NEPHROURETERECTOMY; OPERATION DURATION; OVERALL SURVIVAL; PELVIC LYMPH NODE DISSECTION; PELVIS LYMPHADENECTOMY; PENIS CANCER; PNEUMONIA; PRIORITY JOURNAL; PROSTATE CANCER; REVIEW; SKIN DISEASE; SURGICAL APPROACH; SURGICAL TECHNIQUE; TESTIS CANCER; UROGENITAL TRACT TUMOR; PATHOLOGY; PROCEDURES; UROGENITAL NEOPLASMS;

HUMANS; LYMPH NODE EXCISION; MINIMALLY INVASIVE SURGICAL PROCEDURES; NEOPLASM STAGING; UROGENITAL NEOPLASMS;

EID: 77955208513     PISSN: 08927790     EISSN: None     Source Type: Journal    
DOI: 10.1089/end.2009.0562     Document Type: Review

References (89)

1. Gervasoni JE Jr, Sbayi S, Cady B. Role of lymphadenectomy in surgical treatment of solid tumors: An update on the clinical data. Ann Surg Oncol 2007;14:2443-2462.
2. Farnell MB, Pearson RK, Sarr MG, et al. A prospective randomized trial comparing standard pancreatoduodenectomy with pancreatoduodenectomy with extended lymphade-nectomy in resectable pancreatic head adenocarcinoma. Surgery 2005;138:618-630.
3. Sasako M, Sano T, Yamamoto S, et al. D2 lymphadenectomy alone or with para-aortic nodal dissection for gastric cancer. N Engl J Med 2008;359:453-462.
4. Hollenbeck BK, Taub DA, Miller DC, et al. The regionali-zation of radical cystectomy to specific medical centers. J Urol 2005;174:1385-1389.
5. Yap SA, DeLair SM, Tanaka ST, Kurzrock EA. Current perceptions of resident training in laparoscopic nephrec-tomy. Urology 2009;73:1067-1071.
6. Protzel C, Alcaraz A, Horenblas S, et al. Lymphadenectomy in the surgical management of penile cancer. Eur Urol 2009;55:1075-1088.
7. Kroon BK, Horenblas S, Lont AP, et al. Patients with penile carcinoma benefit from immediate resection of clinically occult lymph node metastases. J Urol 2005;173:816-819.
8. Hegarty PK, Kayes O, Freeman A, et al. A prospective study of 100 cases of penile cancer managed according to European Association of Urology guidelines. BJU Int 2006;98: 526-531.
9. Catalona WJ. Modified inguinal lymphadenectomy for carcinoma of the penis with preservation of saphenous veins: Technique and preliminary results. J Urol 1988;140:306-310.
10. Bevan-Thomas R, Slaton JW, Pettaway CA. Contemporary morbidity from lymphadenectomy for penile squamous cell carcinoma: The M.D. Anderson Cancer Center Experience. J Urol 2002;167:1638-1642.
11. Bishoff JT, Basler JW, Teichman JM. Endoscopic subcutaneous modified inguinal lymph node dissection (ESMIL) for squamous cell carcinoma of the penis [abstract 301]. J Urol 2003.
12. Tobias-Machado M, Tavares A, Ornellas AA, et al. Video endoscopic inguinal lymphadenectomy: A new minimally invasive procedure for radical management of inguinal nodes in patients with penile squamous cell carcinoma. J Urol 2007;177:953-958.
13. Assimos DG, Jarow JP. Role of laparoscopic pelvic lymph node dissection in the management of patients with penile cancer and inguinal adenopathy. J Endourol 1994;8:365-369.
14. Sotelo R, Sanchez-Salas R, Carmona O, et al. Endoscopic lymphadenectomy for penile carcinoma. J Endourol 2007;21: 364-367.
15. Yu HY, Madison RA, Setodji CM, et al. Quality of surveillance for stage I testis cancer in the community. J Clin Oncol 2009;27:4327-4332.
16. Donohue JP, Zachary JM, Maynard BR. Distribution of nodal metastases in nonseminomatous testis cancer. J Urol 1982;128:315-320.
17. Albqami N, Janetschek G. Laparoscopic retroperitoneal lymph-node dissection in the management of clinical stage I and II testicular cancer. J Endourol 2005;19:683-692.
18. van den Belt-Dusebout AW, Nuver J, de Wit R, et al. Long-term risk of cardiovascular disease in 5-year survivors of testicular cancer. J Clin Oncol 2006;24:467-475.
19. Rassweiler JJ, Scheitlin W, Heidenreich A, et al. Laparo-scopic retroperitoneal lymph node dissection: Does it still have a role in the management of clinical stage I non-seminomatous testis cancer? A European perspective. Eur Urol 2008;54:1004-1015.
20. Carver BS, Shayegan B, Serio A, et al. Long-term clinical outcome after postchemotherapy retroperitoneal lymph node dissection in men with residual teratoma. J Clin Oncol 2007;25:1033-1037.
21. Davol P, Sumfest J, Rukstalis D. Robotic-assisted laparo-scopic retroperitoneal lymph node dissection. Urology 2006;67:199.
22. Hellenthal NJ, Ramirez ML, Evans CP, et al. Trends in pelvic lymphadenectomy at the time of radical cystectomy: 1988 to 2004. J Urol 2009;181:2490-2495.
23. Leissner J, Ghoneim MA, Abol-Enein H, et al. Extended radical lymphadenectomy in patients with urothelial bladder cancer: Results of a prospective multicenter study. J Urol 2004;171:139-144.
24. Stein JP, Cai J, Groshen S, Skinner DG. Risk factors for patients with pelvic lymph node metastases following radical cystectomy with en bloc pelvic lymphadenectomy: Concept of lymph node density. J Urol 2003;170:35-41.
25. Herr HW, Bochner BH, Dalbagni G, et al. Impact of the number of lymph nodes retrieved on outcome in patients with muscle invasive bladder cancer. J Urol 2002;167:1295-1298.
26. Konety BR, Joslyn SA, O'Donnell MA. Extent of pelvic lymphadenectomy and its impact on outcome in patients diagnosed with bladder cancer: Analysis of data from the Surveillance, Epidemiology and End Results Program data base. J Urol 2003;169:946-950.
27. Leissner J, Hohenfellner R, Thuroff JW, Wolf HK. Lympha-denectomy in patients with transitional cell carcinoma of the urinary bladder; significance for staging and prognosis. BJU Int 2000;85:817-823.
28. Poulsen AL, Horn T, Steven K. Radical cystectomy: Extending the limits of pelvic lymph node dissection improves survival for patients with bladder cancer confined to the bladder wall. J Urol 1998;160:2015-2020.
29. Stein JP, Lieskovsky G, Cote R, et al. Radical cystectomy in the treatment of invasive bladder cancer: Long-term results in 1,054 patients. J Clin Oncol 2001;19:666-675.
30. Pruthi RS, Smith A, Wallen EM. Evaluating the learning curve for robot-assisted laparoscopic radical cystectomy. J Endourol 2008;22:2469-2474.
31. Finelli A, Gill IS, Desai MM, et al. Laparoscopic extended pelvic lymphadenectomy for bladder cancer: Technique and initial outcomes. J Urol 2004;172:1809-1812.
32. Haber GP, Gill IS. Laparoscopic radical cystectomy for cancer: Oncological outcomes at up to 5 years. BJU Int 2007;100:137-142.
33. Abraham JB, Young JL, Box GN, et al. Comparative analysis of laparoscopic and robot-assisted radical cystectomy with ileal conduit urinary diversion. J Endourol 2007;21:1473-1480.
34. Pruthi RS, Wallen EM. Is robotic radical cystectomy an appropriate treatment for bladder cancer? Short-term onco-logic and clinical follow-up in 50 consecutive patients. Urology 2008;72:617-622.
35. Wang GJ, Barocas DA, Raman JD, et al. Robotic vs open radical cystectomy: Prospective comparison of perioperative outcomes and pathological measures of early oncological efficacy. BJU Int 2008;101:89-93.
36. Partin AW, Mangold LA, Lamm DM, et al. Contemporary update of prostate cancer staging nomograms (Partin Tables) for the new millennium. Urology 2001;58:843-848.
37. Cerny JC, Farah R, Rian R, Weckstein ML. An evaluation of lymphangiography in staging carcinoma of the prostate. J Urol 1975;113:367-370.
38. Raghavaiah NV, Jordan WP Jr. Prostatic lymphography. J Urol 1979;121:178-181.
39. Gil-Vernet JM. Prostate cancer: Anatomical and surgical considerations. Br J Urol 1996;78:161-168.
40. Bader P, Burkhard FC, Markwalder R. et al. Is a limited lymph node dissection an adequate staging procedure for prostate cancer? J Urol 2002;168:514-518.
41. Heidenreich A, Varga Z, Von Knobloch R. Extended pelvic lymphadenectomy in patients undergoing radical prostatectomy: High incidence of lymph node metastasis. J Urol 2002;167:1681-1686.
42. Joslyn SA, Konety BR. Impact of extent of lymphadenectomy on survival after radical prostatectomy for prostate cancer. Urology 2006;68:121-125.
43. Miyake H, Kurahashi T, Hara I, et al. Significance of mi-crometastases in pelvic lymph nodes detected by real-time reverse transcriptase polymerase chain reaction in patients with clinically localized prostate cancer undergoing radical prostatectomy after neoadjuvant hormonal therapy. BJU Int 2007;99:315-320.
44. Schumacher MC, Burkhard FC, Thalmann GN, et al. Good outcome for patients with few lymph node metastases after radical retropubic prostatectomy. Eur Urol 2008;54: 344-352.
45. DiMarco DS, Zincke H, Sebo TJ, et al. The extent of lym-phadenectomy for pTXNO prostate cancer does not affect prostate cancer outcome in the prostate specific antigen era. J Urol 2005;173:1121-1125.
46. Berglund RK, Sadetsky N, DuChane J, et al. Limited pelvic lymph node dissection at the time of radical prostatectomy does not affect 5-year failure rates for low, intermediate and high risk prostate cancer: Results from CaPSURE. J Urol 2007;177:526-530.
47. Ficarra V, Novara G, Artibani W, et al. Retropubic, laparo-scopic, and robot-assisted radical prostatectomy: A systematic review and cumulative analysis of comparative studies. Eur Urol 2009;55:1037-1063.
48. Schroeck FR, Sun L, Freedland SJ, et al. Comparison of prostate-specific antigen recurrence-free survival in a contemporary cohort of patients undergoing either radical retropubic or robot-assisted laparoscopic radical prostatectomy. BJU Int 2008;102:28-32.
49. Prasad SM, Keating NL, Wang Q, et al. Variations in surgeon volume and use of pelvic lymph node dissection with open and minimally invasive radical prostatectomy. Urology 2008;72:647-653.
50. Zorn KC, Katz MH, Bernstein A, et al. Pelvic lymphade-nectomy during robot-assisted radical prostatectomy: Assessing nodal yield, perioperative outcomes, and complications. Urology 2009;74:296-302.
51. Wyler SF, Sulser T, Seifert HH, et al. Laparoscopic extended pelvic lymph node dissection for high-risk prostate cancer. Urology 2006;68:883-887.
52. Silberstein JL, Derweesh IH, Kane CJ. Lymph node dissection during robot-assisted radical prostatectomy: Where do we stand? Prostate Cancer Prostatic Dis 2009;12:227-232.
53. Messing EM, Manola J, Sarosdy M, et al. Immediate hormonal therapy compared with observation after radical prostatectomy and pelvic lymphadenectomy in men with node-positive prostate cancer. N Engl J Med 1999;341:1781-1788.
54. Bhatta-Dhar N, Reuther AM, Zippe C, Klein EA. No difference in six-year biochemical failure rates with or without pelvic lymph node dissection during radical prostatectomy in low-risk patients with localized prostate cancer. Urology 2004;63:528-531.
55. Weight CJ, Reuther AM, Gunn PW, et al. Limited pelvic lymph node dissection does not improve biochemical relapse-free survival at 10 years after radical prostatectomy in patients with low-risk prostate cancer. Urology 2008;71:141-145.
56. Roscigno M, Shariat SF, Margulis V, et al. Impact of lymph node dissection on cancer specific survival in patients with upper tract urothelial carcinoma treated with radical ne-phroureterectomy. J Urol 2009;181:2482-2489.
57. Roscigno M, Shariat SF, Margulis V, et al. The extent of lymphadenectomy seems to be associated with better survival in patients with nonmetastatic upper-tract urothelial carcinoma: How many lymph nodes should be removed? Eur Urol 2009;56:512-518.
58. Bolenz C, Shariat SF, Fernández MI, et al. Risk stratification of patients with nodal involvement in upper tract urothelial carcinoma: Value of lymph-node density. BJU Int 2009;103: 302-306.
59. Kondo T, Nakazawa H, Ito F, et al. Impact of the extent of regional lymphadenectomy on the survival of patients with urothelial carcinoma of the upper urinary tract. J Urol 2007; 178:1212-1217.
60. Miyake H, Hara I, Gohji K, et al. The significance of lym-phadenectomy in transitional cell carcinoma of the upper urinary tract. Br J Urol 1998;82:494-498.
61. Capitanio U, Shariat SF, Isbarn H, et al. Comparison of on-cologic outcomes for open and laparoscopic nephrou-reterectomy: A multi-institutional analysis of 1249 cases. Eur Urol 2009;56:1-9.
62. Waldert M, Remzi M, Klingler HC, et al. The oncological results of laparoscopic nephroureterectomy for upper urinary tract transitional cell cancer are equal to those of open nephroureterectomy. BJU Int 2009;103:66-70.
63. Roupret M, Hupertan V, Sanderson KM, et al. Oncologic control after open or laparoscopic nephroureterectomy for upper urinary tract transitional cell carcinoma: A single center experience. Urology 2007;69:656-661.
64. Hsueh TY, Huang YH, Chiu AW, et al. Survival analysis in patients with upper urinary tract transitional cell carcinoma: A comparison between open and hand-assisted laparoscopic nephroureterectomy. BJU Int 2007;99:632-636.
65. Manabe D, Saika T, Ebara S, et al. Comparative study of oncologic outcome of laparoscopic nephroureterectomy and standard nephroureterectomy for upper urinary tract transitional cell carcinoma. Urology 2007;69:457-461.
66. Busby JE, Brown GA, Matin SF. Comparing lymphade-nectomy during radical nephroureterectomy: Open versus laparoscopic. Urology 2008;71:413-416.
67. Joslyn SA, Sirintrapun SJ, Konety BR. Impact of lymphade-nectomy and nodal burden in renal cell carcinoma: Retrospective analysis of the National Surveillance, Epidemiology, and End Results database. Urology 2005;65:675-680.
68. Chapman TN, Sharma S, Zhang S, et al. Laparoscopic lymph node dissection in clinically node-negative patients undergoing laparoscopic nephrectomy for renal carcinoma. Urology 2008;71:287-291.
69. Blom JH, van Poppel H, Maréchal JM, et al. Radical ne-phrectomy with and without lymph-node dissection: Final Results of European Organization for Research and Treatment of Cancer (EORTC) randomized phase 3 trial 30881. Eur Urol 2009;55:28-34.
70. Blute ML, Leibovich BC, Cheville JC, et al. A protocol for performing extended lymph node dissection using primary tumor pathological features for patients treated with radical nephrectomy for clear cell renal cell carcinoma. J Urol 2004; 172:465-469.
71. Hemal AK, Kumar A, Kumar R, et al. Laparoscopic versus open radical nephrectomy for large renal tumors: A long-term prospective comparison. J Urol 2007;177:862-866.
72. Simmons MN, Kaouk J, Gill IS, Fergany A. Laparoscopic radical nephrectomy with hilar lymph node dissection in patients with advanced renal cell carcinoma. Urology 2007; 70:43-46.
73. Josephson DY, Jacobsohn KM, Link BA, Wilson TG. Robotic-assisted endoscopic inguinal lymphadenectomy. Urology 2009;73:167-171.
74. Bhayani SB, Ong A, Oh WK, et al. Laparoscopic retroperi-toneal lymph node dissection for clinical stage I non-seminomatous germ cell testicular cancer: A long-term update. Urology 2003;62:324-327.
75. Castillo OA, Urena RD, Pinto IF. Laparoscopic retroperito-neal lymph node dissection for stage I and II NSGCT: 10 years' experience. J Urol 2004;171(suppl):247.
76. Abdel-Aziz KF, Anderson JK, Svatek R, et al. Laparoscopic and open retroperitoneal lymph-node dissection for clinical stage I nonseminomatous germ-cell testis tumors. J Endourol 2006;20:627-631.
77. Neyer M, Peschel R, Akkad T, et al. Long-term results of laparoscopic retroperitoneal lymph-node dissection for clinical stage I nonseminomatous germ-cell testicular cancer. J Endourol 2007;21:180-183.
78. Nielsen ME, Lima G, Schaeffer EM, et al. Oncologic efficacy of laparoscopic RPLND in treatment of clinical stage I non-seminomatous germ cell testicular cancer. Urology 2007;70:1168-1172.
79. Cresswell J, Scheitlin W, Gozen A, et al. Laparoscopic ret-roperitoneal lymph node dissection combined with adjuvant chemotherapy for pathological stage II disease in non-seminomatous germ cell tumours: A 15-year experience. BJU Int 2008;102:844-848.
80. Skolarus TA, Bhayani SB, Chiang HC, et al. Laparoscopic retroperitoneal lymph node dissection for low-stage testic-ular cancer. J Endourol 2008;22:1485-1489.
81. Steiner H, Zangerl F, Stöhr B, et al. Results of bilateral nerve sparing laparoscopic retroperitoneal lymph node dissection for testicular cancer. J Urol 2008;180:1348-1353.
82. Steiner H, Peschel R, Janetschek G, et al. Long-term results of laparoscopic retroperitoneal lymph node dissection: A single-center 10-year experience. Urology 2004;63:550-555.
83. Steiner H, Mü ller T, Gozzi C, et al. Two cycles of cisplatin-based chemotherapy for low-volume retroperitoneal stage II nonseminomatous germ cell tumours. BJU Int 2006;98:349-352.
84. Calestroupat JP, Sanchez-Salas R, Cathelineau X, et al. Postchemotherapy laparoscopic retroperitoneal lymph node dissection in nonseminomatous germ-cell tumor. J Endourol 2009;23:645-650.
85. Permpongkosol S, Lima GC, Warlick CA, et al. Post-chemotherapy laparoscopic retroperitoneal lymph node dissection: Evaluation of complications. Urology 2007;69: 361-365.
86. Maldonado-Valadez R, Schilling D, Anastasiadis AG, et al. Post-chemotherapy laparoscopic retroperitoneal lymph-node dissection in testis cancer patients. J Endourol 2007;21: 1501-1504.
87. Stephenson AJ, Gill IS. Laparoscopic radical cystectomy for muscle-invasive bladder cancer: Pathological and oncological outcomes. BJU Int 2008;102:1296-1301.
88. Guru KA, Kim HL, Piacente PM, Mohler JL. Robot-assisted radical cystectomy and pelvic lymph node dissection: Initial experience at Roswell Park Cancer Institute. Urology 2007;69:469-474.
89. Woods M, Thomas R, Davis R, et al. Robot-assisted extended pelvic lymphadenectomy. J Endourol 2008;22:1297-1302.